ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 3 for:    d-plex
Previous Study | Return to List | Next Study

Efficacy and Safety of D-PLEX in the Prevention of Sternal Infection Post Cardiac Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03558984
Recruitment Status : Not yet recruiting
First Posted : June 15, 2018
Last Update Posted : June 15, 2018
Sponsor:
Information provided by (Responsible Party):
PolyPid Ltd.

Brief Summary:

Prospective, Multinational, Multicenter, Randomized, Parallel Controlled, Two arms, Single Blind, Study to Assess the Efficacy and Safety of D-PLEX Administered Concomitantly with the Standard of Care (SOC) IV Prophylactic Antibiotic Treatment vs. SOC in Prevention of Post-Cardiac Surgery Sternal Infections.

Study to assess D-PLEX efficacy and safety in preventing sternal infections over a period of 90 days (3 months) post cardiac surgery with median sternotomy, in patients with high risk for infection compared to the control arm.


Condition or disease Intervention/treatment Phase
Surgical Site Infection Open Heart Surgery Drug: D-PLEX Phase 3

Detailed Description:
This is Phase III study to evaluate the anti-infective efficacy and safety of D-PLEX, a new formulation of extended release of Doxycycline, over a period of 3 months post operation by preventing sternal infection post cardiac surgery in patients above the age of 18, including high risk patients for infection. Study will be conducted in about 40 sites in US and Europe, recruitment period will last about 12 months. D-PLEX will be administered as a single application. For subjects randomized to the investigational treatment arm, D-PLEX treatment will be applied at the end of the index surgery just before closing the chest, as an adjunct to the SOC prophylactic antibiotic treatment. For subjects randomized to the control arm, the surgical treatment will be as per the SOC. Pre- and post-operative care for both arms will be performed per site SOC. Patients will followed-up during 6 months after surgery.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1600 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Eligible subjects will be randomized to either the treatment arm (D-PLEX + SOC prophylactic antibiotic treatment) or to control arm (SOC prophylactic antibiotic treatment only), in a 1:1 ratio.

Subjects will be blinded to the study arm.

Masking: Single (Participant)
Masking Description: Subjects will be blinded to the treatment arm assignment. The study site personnel present at the baseline procedure as well as the physician performing the procedure will be trained not to disclose the treatment arm to the subject, his/her family, to health care providers outside of the surgery department and to the study sponsor.
Primary Purpose: Prevention
Official Title: Prospective, Multicenter, Randomized, Parallel Controlled, Two Arms, Single Blind, Study to Assess the Efficacy and Safety of D-PLEX Administered Concomitantly With the SOC IV Prophylactic Antibiotic Treatment vs. SOC in Prevention of Post-Cardiac Surgery Sternal Infections
Estimated Study Start Date : November 1, 2018
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : March 31, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Surgery

Arm Intervention/treatment
Experimental: D-PLEX + SOC
For subjects randomized to the investigational treatment arm, D-PLEX treatment will be applied at the end of the index surgery just before closing the chest, as an adjunct to the SOC prophylactic antibiotic treatment.
Drug: D-PLEX
D-PLEX is a new formulation of extended release of Doxycycline (active ingredient)

No Intervention: Standard of Care
For subjects randomized to the control arm, the surgical treatment will be as per the SOC.



Primary Outcome Measures :
  1. Infection rate [ Time Frame: within 90 days (3 months) post sternotomy for cardiac surgery ]
    Infection rate as measured by the proportion of subjects with a sternal wound infection event


Secondary Outcome Measures :
  1. Hospitalization days [ Time Frame: 90 days ]
    Average number of Hospitalization days post sternotomy for cardiac surgery, due to sternal infection.

  2. Deep Surgical Wound Infection (DSWI) rates [ Time Frame: 90 days (3 months) post sternotomy ]
    Incidence of DSWI rates

  3. Superficial Surgical Wound Infection (SSWI) rates [ Time Frame: 90 days (3 months) post sternotomy ]
    Incidence of SSWI rates

  4. Antibiotic Treatment [ Time Frame: 90 days (3 months) post sternotomy ]
    Average number of Antibiotic Treatment (overall IV and other administration modes, e.g. PO) days due to Sternal Surgical Site infection.

  5. Surgical re-interventions [ Time Frame: 90 days (3 months) post sternotomy ]
    Number of surgical re-interventions due to Sternal Surgical Site infection

  6. Mortality rate from any reason [ Time Frame: 6 months ]
    Mortality rate from any reason

  7. Mortality rate due to sternal wound infection [ Time Frame: 90 days (3 months) post sternotomy ]
    Mortality rate associated sternal wound infection.


Other Outcome Measures:
  1. Overall hospitalization days [ Time Frame: 6 months ]
    Average number of Overall Hospitalization days post sternotomy for cardiac surgery, including days of readmission due to any reason.

  2. Antibiotic treatment IV [ Time Frame: 90 days (3 months) post sternotomy ]
    Average number of Antibiotic Treatment (IV) days due to Sternal Surgical Site infection (SSWI and DSWI).

  3. Time to sternal infection [ Time Frame: 90 days (3 months) post sternotomy ]
    Time to sternal wound infection (Post Operating Day) post sternotomy.

  4. Analgesic treatment [ Time Frame: 6 months ]
    Average number of analgesic treatment days

  5. Visual Analogue Score (VAS) assessment [ Time Frame: 6 months ]
    VAS score assessment



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects scheduled to elective and/or urgent median sternotomy for cardiac surgery, who are preoperative hemodynamically stable.
  2. Males and females.
  3. Subjects age of 18 and older.
  4. Subjects with both Diabetes Mellitus AND BMI≥30 OR

    Diabetes Mellitus/BMI≥30 AND at least one of the following:

    • Current/Previous smoking history ≥30 pack year
    • Chronic Obstructive Pulmonary Disease (COPD)
  5. Female of childbearing potential should have a negative serum pregnancy test prior to index procedure.

    Note: All female of childbearing potential must agree to use a highly effective method of contraception (such as double barrier, oral or parenteral hormonal, intrauterine device and spermicide) consistently and correctly for the duration of the study.

  6. Subject is willing and able to provide a signed Informed Consent Form and is willing and able to comply with study's procedures including follow-up visits.

Exclusion Criteria:

  1. Subjects undergoing partial sternotomy.
  2. Subjects with any preoperative active significant infection.
  3. Subjects that received oral or IV doxycycline during the last 4 weeks prior to screening.
  4. Subjects with sensitivity to doxycycline and/or to tetracycline family of drugs and/or other study drug ingredients.
  5. Subjects with known allergies to more than 3 substances. (An allergy questionnaire will be filled during the screening process).
  6. Subjects with history of allergic/hypersensitivity reaction to any substance having required hospitalization and/or treatment with intra-venous steroids/epinephrine or in the opinion of the investigator the patient is at high risk of developing severe allergic/hypersensitivity reactions.
  7. Subjects with uncontrolled Asthma (GINA III-IV).
  8. Subjects with chronic urticaria.
  9. Immunocompromised subjects from any reason, at screening.
  10. Subjects with renal failure requiring dialysis.
  11. Subjects scheduled to major organ transplantation and/or to other significant concomitant surgical procedure.
  12. Subjects scheduled for mechanical assist device.
  13. Subjects undergone Cerebro-Vascular Accident (CVA)/Transient Ischemic Attack (TIA) within the past 3 months prior to randomization.
  14. Subjects that have undergone previously, any cardiac surgery through sternotomy.
  15. Subjects with active or previous malignancy in the chest area.
  16. Any subject with active malignancy or with malignancy that has not been in complete remission for at least 5 years. Subjects who have had carcinoma in situ of the cervix, squamous cell carcinoma of the skin and basal cell carcinoma of the skin, are eligible.
  17. Pregnant or breast-feeding women or women of childbearing age not protected by an effective contraceptive method of birth control (such as double barrier, oral or parenteral hormonal, intrauterine device and spermicide).
  18. Subjects enrolled in any intervention study with an investigational medicinal product and/or received any investigational medicinal product within 30 days or 5½ half-lives of the product prior to enrollment (whichever is longer).
  19. In the opinion of investigator, subject is not eligible to participate in the study and/or to comply with protocol requirements (e.g. due to a cognitive, medical condition or residency distanced from site that may jeopardize Follow-Up visits attendance etc.).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03558984


Contacts
Contact: Ilana Sufaro +972-74-7195700 ext +972747195774 ilana.s@polypid.com
Contact: Noa Kirshenboim, PhD +972-74-7195700 ext +972747195774 noa.k@polypid.com

Locations
Israel
Soroka Medical Center Not yet recruiting
Beer Sheva, Israel
Contact: Adelina Steinberg    08-6400962    adelinaba@clalit.org.il   
Sponsors and Collaborators
PolyPid Ltd.
Investigators
Study Director: Noa Kirshenboim, PhD VP Clinical

Responsible Party: PolyPid Ltd.
ClinicalTrials.gov Identifier: NCT03558984     History of Changes
Other Study ID Numbers: D-PLEX 302
First Posted: June 15, 2018    Key Record Dates
Last Update Posted: June 15, 2018
Last Verified: June 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by PolyPid Ltd.:
Surgical Site Infection (SSI), Cardiac Surgery, Open Heart Surgery, Infection

Additional relevant MeSH terms:
Infection
Communicable Diseases
Surgical Wound Infection
Wound Infection
Postoperative Complications
Pathologic Processes